VYNE Therapeutics Operating Expenses 2016-2024 | VYNE

VYNE Therapeutics operating expenses from 2016 to 2024. Operating expenses can be defined as the sum of all operating expenses for the given industry.

VYNE Therapeutics Operating Expenses 2016-2024 | VYNE

VYNE Therapeutics operating expenses from 2016 to 2024. Operating expenses can be defined as the sum of all operating expenses for the given industry.
Related Stocks
Company NameMarket
Cap
Zoetis (ZTS)$76.8B
Chugai Pharmaceutical (CHGCY)$66.9B
Takeda Pharmaceutical (TAK)$42.4B
Sandoz Group AG (SDZNY)$20.6B
Merck (MKKGY)$20B
Astellas Pharma (ALPMY)$17.7B
United Therapeutics (UTHR)$16.6B
Summit Therapeutics (SMMT)$16B
Neurocrine Biosciences (NBIX)$15.3B
Shionogi (SGIOY)$12.5B
Orion OYJ (ORINY)$7.5B
Madrigal Pharmaceuticals (MDGL)$7.1B
Stevanato Group S.p.A (STVN)$6.5B
Corcept Therapeutics (CORT)$6.4B
Hikma Pharmaceuticals Plc (HKMPF)$5.9B
Ionis Pharmaceuticals (IONS)$5.2B
Ono Pharmaceutical (OPHLF)$4.9B
Grifols, S.A (GRFS)$4.8B
Crinetics Pharmaceuticals (CRNX)$3.7B
Catalyst Pharmaceuticals (CPRX)$2.9B
Recursion Pharmaceuticals (RXRX)$2.8B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.7B
Centessa Pharmaceuticals (CNTA)$2.2B
Soleno Therapeutics (SLNO)$2.1B
Hypermarcas (HYPMY)$1.9B
NewAmsterdam Pharma (NAMS)$1.9B
Indivior (INDV)$1.7B
BioCryst Pharmaceuticals (BCRX)$1.7B
Evotec AG (EVO)$1.5B
Guardian Pharmacy Services (GRDN)$1.4B